On February 7, 2022 Immagene, a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita (WSE: SLV), one of the largest preclinical contract research organizations in Europe, reported their cooperation on an integrated drug discovery project (Press release, Selvita, FEB 7, 2022, View Source;utm_medium=rss&utm_campaign=immagene-and-selvita-announce-integrated-drug-discovery-cooperation [SID1234607810]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is guiding and tapping into Selvita’s extensive drug discovery capabilities. Selvita is responsible for a broad range of drug discovery activities including medicinal chemistry supported by computational chemistry, in vitro pharmacology, DMPK and recombinant protein production. Immagene and Selvita are now extending their cooperation.

Edyta Jaworska, VP Sales, Drug Discovery Europe and Asia at Selvita Group, comments:
"We are truly delighted with the extension of our close collaboration with Immagene. For Selvita’s team, it is a perfect opportunity to leverage the full scope of our integrated drug discovery capabilities. This project is exceptionally promising in terms of its therapeutic potential and unique chemistry."

Maarten Ligtenberg, PhD, Chief Executive Officer of Immagene, said:
"We are confident that our collaboration with Selvita will help us achieve our aim of generating potent first in class small-molecule immune-oncology assets. The rapid turnaround and effective communication allow for the swift development of our programs. We look forward to a longstanding, joint effort to develop innovative therapeutics."

To date, Selvita has delivered numerous promising compounds for biology and DMPK screening, and the project has entered the lead optimization phase. The ultimate aim of the cooperation is to provide Immagene with a clinical candidate for unmet immuno-oncology needs. The continued collaboration will help accelerate Immagene’s pipeline expansion efforts by leveraging Selvita’s fully integrated R&D platform and unique experience in oncology drug discovery and development.

On February 7, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported that the company will report 2H and Full Year report 2021 and hold a live webinar (in English) for investors, analysts and media on (Press release, Herantis Pharma, FEB 7, 2022, View Source,c3499761 [SID1234607777]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thursday, March 3rd, 2022, at 10:00 EET / 9:00 CET.

Herantis will publish the company’s 2H and Full Year 2021 report on March 3, 2022, at 8:00 EET /7:00 CET.

The management will present Herantis and comment on the 2H and Full Year 2021 Report followed by a live Q&A session. Please join the webinar a few minutes in advance.

On February 7, 2022 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences (Press release, Myovant Sciences, FEB 7, 2022, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-present-upcoming-investor-conferences-4 [SID1234607794]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:00 p.m. Eastern Time.

Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022, at 9:50 a.m. Eastern Time.
Investors and the general public are invited to listen to the webcasts, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

On February 7, 2022 Cerus Corporation (Nasdaq: CERS) reported that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference (Press release, Cerus, FEB 7, 2022, View Source [SID1234607811]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Wednesday, February 16th at 9:00 a.m. EST, Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference. BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.

On Friday, February 18th at 12:00 p.m. EST, Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 11th Annual SVB Leerink Global Healthcare Conference. To listen to the webcast, please visit the investor relations section of Cerus’ website at: ir.cerus.com.

On February 6, 2022 Statera Biopharma, Inc. (NASDAQ: STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, reported that it entered into a securities purchase agreement with a certain institutional investor to purchase approximately $2.0 million worth of its common stock and warrants in a registered direct offering (Press release, Cleveland BioLabs, FEB 6, 2022, View Source [SID1234607784]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 2.0 million shares of its common stock and warrants to purchase approximately 2.0 million shares of common stock. The warrants will be exercisable immediately, have an exercise price of $1.00 per share, and will expire five years from the initial exercise date. The purchase price for one share of common stock and one warrant will be $1.00.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $2.0 million, before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about February 9, 2022, subject to the satisfaction of customary closing conditions.

EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering. Bridgeway Capital Partners is acting as the Company’s financial advisor.

Anthony L.G., PLLC is acting as legal counsel to Statera Biopharma, Inc. and Carmel, Milazzo & Feil LLP is acting as legal counsel to EF Hutton for the offering.

The proposed offering of the common stock and warrants described above is being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-238578) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May 29, 2020, and the accompanying prospectus contained therein.

The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at View Source or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at [email protected], or by telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.